Merck Research Laboratories, Cardiometabolic Disease Biology, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Merck Research Laboratories, Cardiometabolic Disease Biology, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Drug Discov Today. 2014 Sep;19(9):1435-9. doi: 10.1016/j.drudis.2014.04.018. Epub 2014 May 2.
Prevention and treatment of thromboembolic disorders with minimal bleeding risk remains a significant unmet medical need. Studies in Factor XI (FXI)-deficient humans and experimental animal models suggest that targeting FXI in humans provides antithrombotic benefits with reduced bleeding liability compared with current standard of care. In this review, we describe an exciting era in the discovery and development of antithrombotic agents as multiple therapeutic modalities for FXI(a) inhibition progress through preclinical and clinical development.
预防和治疗血栓栓塞性疾病，同时最大限度地降低出血风险，仍然是一个重大的未满足的医学需求。FXI 缺乏症人类和实验动物模型的研究表明，与当前的标准治疗相比，靶向 FXI 可在人类中提供抗血栓益处，同时降低出血风险。在这篇综述中，我们描述了一个激动人心的时代，作为抗血栓药物的发现和开发，多种 FXI(a)抑制治疗方法正在通过临床前和临床开发阶段。
